Abstract 1571
Background
Papillary carcinoma is the most common type of thyroid cancer and if it is not treated early, it can spread throughout the body. Therefore, the first line of treatment for papillary thyroid cancer is the surgery by removing part of or the entire thyroid. Our study aims to establish the most effective surgical procedure (total thyroidectomy or partial thyroidectomy) to achieve better survival for stage I and II papillary carcinoma and evaluate the effect of the ethnicity, sex and age on patients' survival undergoing these surgical techniques.
Methods
We extracted the data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries. We retrieved data of 3691 patients diagnosed with papillary thyroid cancer in 2010. We evaluated the 5-year overall survival of patients using the log-rank test. Patients were grouped into two groups. The first one underwent thyroid lobectomy (242) and the second underwent total thyroidectomy (3449). Patients were further grouped according to ethnicity (white, black, American or Asian), sex (female or male) and age group.
Results
We found that total thyroidectomy was associated with better 5-year overall survival rates in patients with early stage papillary carcinoma, compared to lobectomy (98.1% and 96.5%, respectively, P = 0.021). Moreover, total thyroidectomy showed better survival rates in females than males (98.6% and 95.7%, respectively, p = 0.000) and in young patients aged between 20-39 years (99.8%, p = 0.000). Meanwhile, surgical techniques were not significantly associated with patients’ ethnicity.
Conclusions
Total thyroidectomy was superior to lobectomy in early stages papillary thyroid carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sara Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3059 - Intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial
Presenter: Rongxin Zhang
Session: Poster Display session 2
Resources:
Abstract
3082 - Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of TRIBE and TRIBE-2 studies by GONO
Presenter: Emanuela Dell'Aquila
Session: Poster Display session 2
Resources:
Abstract
3618 - Drug holidays and overall survival in patients treated for metastatic colorectal cancer
Presenter: Silvio Ken Garattini
Session: Poster Display session 2
Resources:
Abstract
6111 - Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)
Presenter: Michael Geissler
Session: Poster Display session 2
Resources:
Abstract
1042 - A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastastic colorectal cancer : results of phase I of the PERMAD trial
Presenter: Thomas Seufferlein
Session: Poster Display session 2
Resources:
Abstract
3291 - Microsatellite Instability (MSI) status and prognosis in colorectal cancer: meta-analysis
Presenter: James Toh
Session: Poster Display session 2
Resources:
Abstract
2046 - Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer.
Presenter: Miriam Koopman
Session: Poster Display session 2
Resources:
Abstract
2589 - Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
Presenter: Stefan Kasper
Session: Poster Display session 2
Resources:
Abstract
4944 - POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers
Presenter: Maria Elena Elez Fernandez
Session: Poster Display session 2
Resources:
Abstract
2042 - The accuracy of the clinical PCI score in patients with peritoneal carcinomatosis of colorectal cancer
Presenter: Nadine De Boer
Session: Poster Display session 2
Resources:
Abstract